Pay in 4 interest-free payments of $7.46 Learn more
Ships within 48 hours · Estimated delivery Sep 1 - Sep 6
Clinical outcomes in t(4;14) multiple myeloma: a chemotherapy-sensitive disease characterized by rapid relapse and alkylating agent resistance
While the science in animals is intriguing, the lack of controlled human trials especially in women makes their use highly uncertain and potentially risky
This senolytic peptide disrupts the FOXO4-p53 interaction that maintains senescent cell viability
Bioinspired and biomimetic delivery platforms for cancer vaccines
doi: 10.3389/fcimb.2021.630812 Received 18 November 2020 Accepted 05 February 2021 Published 12 March 2021 Volume 11 - 2021 Edited by Justin Boddey, Walter and Eliza Hall Institute of Medical Research, Australia Reviewed by Sandra Duffy, Griffith University, Australia
.webp)
